Volrustomig

沃苏米单抗

Report date: 2026/05/18 20:02:07

Base Information

Drug NameVolrustomig
Drug Alias NameMEDI-5752MEDI5752
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed cell death protein 1 inhibitorsCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUterine Cervical Neoplasms +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[42] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesInstitut BergoniéThe University Of ChicagoAstrazeneca Plc +[8] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUterine Cervical Neoplasms +[16] 
Inactive IndicationsEsophageal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A